# HST-1011

Source: https://onco.cc/drugs/hst-1011/  
OnCo record `hst-1011` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

HST-1011 is a small-molecule inhibitor from HotSpot Therapeutics, Inc, in registered phase 2 trials for metastatic cancer.

## Summary

HST-1011 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by HotSpot Therapeutics, Inc, in metastatic cancer. Described in the registry record as a cbl-b inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Also known as: CBL-B inhibitor
- Tags: pipeline; ctgov-ingest; registry-only
- Code: HST-1011
- Modality: Small-molecule inhibitor
- Mechanism: Described in the registry record as a cbl-b inhibitor; the trial entries below carry the sponsor's wording.

## Sources

- ClinicalTrials.gov: trials of HST-1011: https://clinicaltrials.gov/search?intr=HST-1011

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- trials: [A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody](https://onco.cc/trials/nct05662397/)

---
JSON: https://onco.cc/api/v1/entities/hst-1011.json